These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 18392627)

  • 1. Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability.
    Gunia S; Albrecht K; Koch S; Herrmann T; Ecke T; Loy V; Linke J; Siegsmund M; May M
    World J Urol; 2008 Jun; 26(3):243-50. PubMed ID: 18392627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy.
    May M; Siegsmund M; Hammermann F; Loy V; Gunia S
    Scand J Urol Nephrol; 2007; 41(5):375-81. PubMed ID: 17853019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroendocrine Differentiation in Metastatic Conventional Prostate Cancer Is Significantly Increased in Lymph Node Metastases Compared to the Primary Tumors.
    Genitsch V; Zlobec I; Seiler R; Thalmann GN; Fleischmann A
    Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28788048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer.
    Zellweger T; Günther S; Zlobec I; Savic S; Sauter G; Moch H; Mattarelli G; Eichenberger T; Curschellas E; Rüfenacht H; Bachmann A; Gasser TC; Mihatsch MJ; Bubendorf L
    Int J Cancer; 2009 May; 124(9):2116-23. PubMed ID: 19117060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy.
    Cowen D; Troncoso P; Khoo VS; Zagars GK; von Eschenbach AC; Meistrich ML; Pollack A
    Clin Cancer Res; 2002 May; 8(5):1148-54. PubMed ID: 12006531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low endoglin vascular density and Ki67 index in Gleason score 6 tumours may identify prostate cancer patients suitable for surveillance.
    Josefsson A; Wikström P; Egevad L; Granfors T; Karlberg L; Stattin P; Bergh A
    Scand J Urol Nephrol; 2012 Aug; 46(4):247-57. PubMed ID: 22452635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Relationship of neuroendocrine differentiation to biological behavior of prostate cancer].
    Wu XL; Huang KT; Chen W; Chen L; Dong L; Yu ZX
    Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):472-5. PubMed ID: 19567097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of >1000 prostatectomies.
    Tretiakova MS; Wei W; Boyer HD; Newcomb LF; Hawley S; Auman H; Vakar-Lopez F; McKenney JK; Fazli L; Simko J; Troyer DA; Hurtado-Coll A; Thompson IM; Carroll PR; Ellis WJ; Gleave ME; Nelson PS; Lin DW; True LD; Feng Z; Brooks JD
    Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):264-70. PubMed ID: 27136741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. De novo neuroendocrine transdifferentiation in primary prostate cancer-a phenotype associated with advanced clinico-pathologic features and aggressive outcome.
    Abdulfatah E; Reichert ZR; Davenport MS; Chinnaiyan AM; Dadhania V; Wang X; Mannan R; Kunju LP; Hollenbeck BK; Montgomery JS; Kaffenberger SD; Morgan TM; Alva AS; Palapattu GS; Vaishampayan UN; Alumkal JJ; Spratt DE; Udager AM; Mehra R
    Med Oncol; 2021 Feb; 38(3):26. PubMed ID: 33586037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroendocrine differentiation in prostate cancer.
    Cerović SJ; Brajusković GR; Vukotić Maletić VD; Mićić SR
    Vojnosanit Pregl; 2004; 61(5):513-8. PubMed ID: 15551804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy.
    Bubendorf L; Sauter G; Moch H; Schmid HP; Gasser TC; Jordan P; Mihatsch MJ
    J Pathol; 1996 Apr; 178(4):437-41. PubMed ID: 8691323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoreactivity for prostate specific antigen and Ki67 differentiates subgroups of prostate cancer related to outcome.
    Hammarsten P; Josefsson A; Thysell E; Lundholm M; Hägglöf C; Iglesias-Gato D; Flores-Morales A; Stattin P; Egevad L; Granfors T; Wikström P; Bergh A
    Mod Pathol; 2019 Sep; 32(9):1310-1319. PubMed ID: 30980038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of neuroendocrine differentiation in patients with Gleason score 8-10 prostate cancer treated with primary radiotherapy.
    Krauss DJ; Hayek S; Amin M; Ye H; Kestin LL; Zadora S; Vicini FA; Cotant M; Brabbins DS; Ghilezan MI; Gustafson GS; Martinez AA
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e119-25. PubMed ID: 21596486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer.
    Lobo J; Rodrigues Â; Antunes L; Graça I; Ramalho-Carvalho J; Vieira FQ; Martins AT; Oliveira J; Jerónimo C; Henrique R
    Urol Oncol; 2018 Apr; 36(4):161.e7-161.e17. PubMed ID: 29174711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival predictors in patients with prostate adenocarcinoma with hormonal blockade.
    Angulo JC; Redondo C; Sánchez-Chapado M; Colás B; Ropero S; López JI
    Pathol Res Pract; 2016 Oct; 212(10):899-903. PubMed ID: 27502465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Ki67 in the prognosis of prostate cancer].
    Huang T; Liu JJ; Zhang JW; Zhu ZC; Wang T; Cai L; Chen ZQ
    Zhonghua Nan Ke Xue; 2019 Dec; 25(12):1088-1092. PubMed ID: 32251559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02.
    Pollack A; DeSilvio M; Khor LY; Li R; Al-Saleem TI; Hammond ME; Venkatesan V; Lawton CA; Roach M; Shipley WU; Hanks GE; Sandler HM
    J Clin Oncol; 2004 Jun; 22(11):2133-40. PubMed ID: 15169799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ki-67, mini-chromosome maintenance 2 protein (MCM2) and geminin have no independent prognostic relevance for cancer-specific survival in surgically treated squamous cell carcinoma of the penis.
    May M; Burger M; Otto W; Hakenberg OW; Wieland WF; May D; Hofstädter F; Götz S; Niessl N; Fritsche HM; Birnkammer K; Gilfrich C; Peter J; Jain A; Koch S; Lebentrau S; Riedmiller H; Rössler W; Denzinger S; Brookman-May S; Gunia S
    BJU Int; 2013 Aug; 112(4):E383-90. PubMed ID: 23305250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x.
    Pollack A; Cowen D; Troncoso P; Zagars GK; von Eschenbach AC; Meistrich ML; McDonnell T
    Cancer; 2003 Apr; 97(7):1630-8. PubMed ID: 12655519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Correlation between PSCA Expression and Neuroendocrine Differentiation in Prostate Cancer.
    Xiang Q; Zhu Z; Luo L; Wang J; Liu Y; Deng Y; Zhou M; Zhao Z
    Biomed Res Int; 2020; 2020():5395312. PubMed ID: 33029516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.